Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Dyadic International, Inc. - Common Stock
(NQ:
DYAI
)
0.9075
+0.0811 (+9.81%)
Streaming Delayed Price
Updated: 12:34 PM EST, Dec 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dyadic International, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Dyadic Appoints Doug Pace to Its Executive Leadership Team
October 09, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
October 05, 2023
Via
Benzinga
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic
October 05, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at Industry and Investor Events in October
September 29, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
September 26, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
September 19, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic International Earnings Perspective: Return On Capital Employed
↗
March 30, 2023
Via
Benzinga
Earnings Outlook For Dyadic International
↗
March 28, 2023
Via
Benzinga
Dyadic to Present at BioProcess International
September 12, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
August 07, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
July 26, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
July 24, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
June 21, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Participate at Upcoming Events in June
June 01, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Participate at Two Industry Events in May
May 10, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™
May 08, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
April 26, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
April 18, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
April 12, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at World Vaccine Congress Washington 2023
March 30, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
March 15, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
March 07, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
March 01, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
February 10, 2023
Via
Benzinga
Dyadic to Participate in Two Upcoming Investor Conferences
February 02, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
January 24, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Sale of Equity Interest in Alphazyme
January 19, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
January 04, 2023
Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA...
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
December 14, 2022
From
Dyadic International, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today